Compare AFLAC Incorporated (AFL) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs Heron Therapeutics Inc — how do they compare? AFLAC Incorporated trades at $121.06 (market cap $61.13B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: AFLAC Incorporated is far larger — about 964× Heron Therapeutics Inc's market cap, and AFLAC Incorporated pays a 2% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AFL | HRTX | |
|---|---|---|
Market Cap | $61.13B | $63.41M |
Sector | Financials | Health |
52-Week High | $129.55 | $1.49 |
52-Week Low | $103.55 | $0.32 |
Enterprise Value | $71.08B | $161.31M |
Dividend Yield | 2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $124.61, down 1.62% with recent earnings misses and bearish technical signals. The stock shows mixed fundamentals with a P/E of 13.44 and net income margin of 26.79%, though revenue declined to $17.36B in 2025. Recent news highlights Japan unit challenges and dividend reliability, with the company maintaining 43 consecutive years of dividend increases.
Outlook remains cautious with analyst consensus at Hold (56.24%) and price target of $117.60 below current levels. Key risks include foreign exchange headwinds and competitive pressures, while the dividend yield and strong cash flow provide support for income-focused investors amid near-term volatility.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
